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Background: Acupuncture is an alternative therapy that is widely used to treat various neurodegenerative diseases
and effectively improve cognitive and memory impairment. The aim of this study was to examine whether
acupuncture stimulation at the Baihui (GV20) acupoint improves memory defects caused by scopolamine (SCO)
administration in rats. We also investigated the effects of acupuncture stimulation at GV20 on the cholinergic
system as well as the expression of brain-derived neurotrophic factor (BDNF) and cAMP-response element-binding
protein (CREB) in the hippocampus.
Methods: SCO (2 mg/kg, i.p.) was administered to male rats once daily for 14 days. Acupuncture stimulation at
GV20 was performed for 5 min before SCO injection. After inducing cognitive impairment via SCO administration,
we conducted a passive avoidance test (PAT) and the Morris water maze (MWM) test to assess behavior.
Results: Acupuncture stimulation at GV20 improved memory impairment as measured by the PAT and reduced the
escape latency for finding the platform in the MWM test. Acupuncture stimulation at GV20 significantly alleviated
memory-associated decreases in the levels of choline acetyltransferase (ChAT), BDNF and CREB proteins in the
hippocampus. Additionally, acupuncture stimulation at GV20 significantly restored the expression of choline
transporter 1 (CHT1), vesicular acetylcholine transporter (VAChT), BDNF and CREB mRNA in the hippocampus.
These results demonstrate that acupuncture stimulation at GV20 exerts significant neuroprotective effects against
SCO-induced neuronal impairment and memory dysfunction in rats.
Conclusions: These findings suggest that acupuncture stimulation at GV20 might be useful in various
neurodegenerative diseases to improve cognitive functioning via stimulating cholinergic enzyme activities and
regulating BDNF and CREB expression in the brain.
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Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder of the brain that is characterized by deterioration
of memory and cognitive function due to cholinergic
nervous system dysfunction [1]. Decreased cholinergic
function in the brain, as primarily observed in patients with
AD, can result in a decline in memory and cognitive
function [2]. Accordingly, various cholinergic drugs have
been approved to treat or alleviate AD, and they exert their
therapeutic effects by counteracting acetylcholine (ACh)
deficits and consequently enhancing ACh levels in the
brain [3]. In fact, the most common therapy for AD
is administration of acetylcholinesterase (AChE) inhibitors,
such as donepezil, galantamine, and rivastigmine, which
temporarily increase the availability of ACh at cholinergic
synapses [4]. Nevertheless, new drugs used to treat
AD patients are limited due to their short half-lives
and excessive side effects caused by peripheral cholinergic
system activation and hepatotoxicity, the most frequent and
critical side-effect of these drugs [5]. Thus, an alternative
treatment modality for AD patients is required.
Scopolamine (SCO) is a tropane alkaloid drug that
exhibits competitive antagonism at muscarinic acetylcholine
receptors (mAChRs) by interfering with cholinergic
transmission in the central nervous system CNS; [6].
Therefore, SCO administration to animals is used as
an experimental model of the cognitive deterioration
and memory disturbances in AD; this animal model is
frequently used to screen for drugs that have potential
therapeutic value in AD-type dementia patients [7-9]. SCO
administration not only induces dysregulation of the
cholinergic neuronal pathway and memory circuits in
the CNS but also reduces the expression of brain-derived
neurotrophic factor (BDNF) and cAMP-response element-
binding protein (CREB) in the brain; thus, BDNF and CREB
may act a novel therapeutics to treat hippocampal dysfunc-
tion and memory deficits [10,11]. BDNF is believed to be
responsible for synaptic plasticity and memory perform-
ance, particularly in the water maze test, and is coupled to
CREB activation [12,13]. Several studies demonstrated that
hippocampal BDNF and CREB are important in long-term
memory formation [14], and play important roles in patho-
logical conditions and neurodegenerative diseases such as
AD [15,16].
In East Asian nations, acupuncture is used widely to
treat many neurodegenerative disorders, including AD,
Parkinson’s disease (PD) and dementia [17]. Its therapeutic
effects and mechanism of action have been investigated in
both clinical and animal studies. This alternative therapy is
known to modulate biochemical balance in the CNS and to
maintain homeostasis [18]. Specifically, Baihui (GV20) is
one of the most important acupoints targeted to alleviate
neurodegenerative disorders and cognitive impairment in
acupuncture treatment [19]. Several studies showed thatacupuncture stimulation at GV20 reduces cerebral infarct
and increases dopamine levels in the brain tissue of
ischemia-reperfusion injured rats [20], and reduces the
amount of apoptotic neurons in the hippocampal CA1 area
of rats with vascular dementia [19]. Although a brief report
of the anti-dementia or anti-ischemic activity of GV20
acupuncture stimulation has been published, whether
GV20 acupuncture stimulation therapeutic efficacy in
alleviating spatial cognitive function following repeated
SCO-induced neuronal impairment is due to cholinergic
system regulation or BDNF and CREB expression remains
unknown [21]. Indeed, one study failed to demonstrate a
therapeutic effect of acupuncture on AD [22]. Such major
differences could be attributable to differences in acupunc-
ture stimulation parameters, as selection of appropriate
stimulation parameters is a crucial factor in the efficacy of
acupuncture [23]. Therefore, it is appropriate to investigate
changes in spatial cognitive function and neuronal
biomarkers in SCO-treated cognitive impairment to
better understand the therapeutic effects and mechanisms
of action of acupuncture stimulation at GV20.
The aim of the present study was to evaluate the ability
of acupuncture stimulation at GV20 to improve learning
and memory in rats exposed to repeated SCO-induced
memory deficits as measured by their performance in the
passive avoidance test (PAT) and the Morris water maze
(MWM) test. We also investigated how these activities were
related to the cholinergic system and the expression of
CREB and BDNF in the CNS, and whether acupuncture
stimulation exerted anti-AD activity in this model to eluci-
date neural mechanisms underlying the memory-enhancing
effect of acupuncture stimulation.
Methods
Animals
Adult male Sprague–Dawley (SD) rats weighing 220–
240 g were obtained from Samtako Animal Co. (Seoul,
Korea). The rats were housed in a limited-access rodent
facility with up to five rats per polycarbonate cage. The
room controls were set to maintain the temperature
at 22 ± 2°C and the relative humidity at 55 ± 15%. Cages were
lit by artificial light for 12 h each day. Sterilized drinking
water and standard chow diet were supplied ad libitum to
each cage during the experiments. The animal experiments
were conducted in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
(NIH Publications No. 80–23), revised in 1996, and were
approved by the Kyung Hee University Institutional Animal
Care and Use Committee. All animal experiments began at
least 7 days after the animals arrived.
Experimental groups
In order to develop learning and memory deficits in the
brain, the rats were intraperitoneally injected with 2 mg/kg
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14 days. Normal animals received saline instead of SCO as
a vehicle control. Different rats in an experimental
group were subjected to either behavioral testing or
immunohistochemistry. The rats were randomly divided
into five groups of six or seven individuals as follows:
normal group (SAL group, n = 7), the SCO-induced and
saline-treated group (SCO group as a control, n = 7), the
SCO-induced and Baihui (GV20) acupoint-stimulated
group (SCO +GV20 group, n = 7), the SCO-induced and
Yangji (TE4) acupoint-stimulated group (SCO+TH4
group, n = 6), and SCO-induced and non-acupoint (on
the tail)-stimulated group (SCO+TA group, n = 6) every
daily for 5 min before the SCO injection. Scopolamine
hydrobromide were purchased from Sigma-Aldrich
Chemical Co. (St Louis, MO, USA). The experimental
schedule of drug administration, acupuncture stimulation
and behavioral tests is shown in Figure 1.
Acupuncture stimulation
Acupuncture stimulation was bilaterally performed
every day for 5 min before the SCO injection during
the SCO-injection period. The acupuncture stimulation
was performed as previously described [24]. The GV20
acupoint, meeting point on the Governing vessel with the
six yang channels, is anatomically located on the midsagittal
line, at the intersection of a line connecting the right and
left ear apices [25]. The acupoint on tail and the Yangji
acupoint were selected as a non-acupoint and a comparison
acupoint, respectively. As a comparable control acupoint,
we also performed the stimulation to another acupoint, the
TE4 acupoint, on hand Shaoyang triple energizer meridian,
is located at the midpoint of the dorsal crease of the wrist,
in the depression on the ulnar side of the tendon of
the extensor muscle of the finger [26,27]. In addition,
the non-acupoint needling was performed at one-fifth
point of tail length from the proximal end of the tail to
avoid the tail acupoints located at proximal or distal
region of the tail. Sterilized disposable stainless steel
acupuncture needles (0.30 × 25 mm, Suzhou KangnianFigure 1 Experimental schedules for scopolamine (SCO) administratio
was designed to explore the efficacy of acupuncture therapy in healing ch
using behavioral and neurobiological methodologies. All rats excluding the
rats were subjected to the Morris water maze (MWM) and the passive avoi
tissues was collected immediately. SCO: scopolamine; IHC: ImmunohistocheMedical Devices Co., Ltd., Shzhou, China) were inserted
perpendicularly as deep as 2–3 mm at GV20 or TE4
acupoint. The depth of needle insertion at each acupoint
was arbitrarily determined based on several previously
studies [28] and in the animal acupuncture atlas [21].
During the acupuncture procedure, rats were gently
handled entirely to minimize stress in the rats. We
did not carry out sham acupuncture for control. The
SAL and SCO groups were handled for 5 min to a
calming effect, instead of acupuncture stimulation,
similar to what we described previously [24].
Passive avoidance test
The test was basically performed according to the
step-through method. The Gemini Avoidance System
(SD Instruments., San Diego, CA, USA) was used for
this experiment. Basically, the step-through passive
avoidance apparatus (PAA) consists of a tilting floor
acrylic box divided into two-compartments, a lightened
compartment connected to a darkened compartments by
an automatic guillotine door and a control unit generating
an electric shock (Behbood Pardaz Co., Ghaem, Iran). The
electric shock can be delivered to the grid floor, made of
stainless steel rods (3 mm diameter) spaced 1 cm apart, in
both compartments. First, the rats were given trials to
acquisition test in the apparatus. In the training session, a
rat was placed in a lightened compartment of the PAA
facing away from the entrance to the dark compartment,
and then the guillotine door was opened. Because of
intrinsic preference to the dark environment, the rat
immediately entered the dark compartment and the
door was closed. During acquisition test, the latency
time before entry into the dark compartment was recorded
for each rat. After 30 min, the rats were placed in
the lightened compartment once again. After entering
the dark compartment, the guillotine door was closed
and subsequently a mild electrical shock (0.5 mA)
was applied for 3 s. The retention test was started
24 h after the acquisition trial for training. The rat was
again placed in the lightened compartment and then to induce spatial memory impairments in rats. The experiment
ronic SCO-induced spatial memory impairment in an animal model
SAL group received SCO injection. Two weeks after SCO injection, the
dance test (PAT). After behavioral testing, rats were sacrificed and brain
mistry.
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rat was placed in the PAA as previously described
and the time required for the rat to enter the dark
compartment was measured for a maximum period of
3 min in the same method with the acquisition test.
The rat did not enter the dark compartment within
this period received a latency time of 180 s.
Morris water maze test
The MWM test was performed in a small circular pool
(2.0 m in diameter and 0.35 m deep) made of polypropylene
and internally painted white. The pool was half-filled with
water to a depth of 30 cm. The water in the pool was made
opaque by adding 1 kg skim milk powder and continuously
maintained at 22 ± 2°C. The pool was divided into four
quadrants of equal area. During the MWM test, an escape
platform (15 cm in diameter) was located in one of four
sections of the pool, hidden 1.5 cm below the water surface
and approximately 50 cm from the sidewalls. Several visual
cues were placed around the pool in plain sight of the
animals. A digital camera was mounted to the ceiling
straight above the center of the pool and was connected to
a computerized recording system equipped with a tracking
program (S-MART; PanLab Co., Barcelona, Spain), which
permitted on- and off-line automated tracking of the paths
taken by the rats. The MWM test was initiated on the 14th
day after the SCO administration commenced. The animals
received three trials per day. The rats were trained to find
the hidden platform, which remained in a fixed location
throughout the test. The trials lasted for a maximum of
180 s, and the escape latency was expressed by the
swimming time to find the submerged platform in the pool.
The animals were tested with three trials per day for 5 days,
and they received a 60-s probe trial on the sixth day.
Finding the platform was defined as staying on it for at least
4 s before the acquisition time of 180 s ended. When the
rat failed to find the platform in the limited time in first trial
of hidden platform test, the rats should be placed on the
platform for 20 s and assigned a latency of 180 s. Between
one trail and the next, the water in the pool was stirred to
remove olfactory traces of previous swim patterns. The
entire schedule proceeded for 6 days and each animal had
three trials for training per day with a 40–50 min inter-trial
interval. For the probe trial, a rat was placed in the quadrant
located diagonally from the target quadrant and allowed to
swim to the quadrant from which the escape platform had
been removed for a maximum of 60 s. The probe trial was
expressed by the ratio of the time spent (or the distance
traveled) in searching for the platform in the target
quadrant to the total duration spent swimming in the pool.
Open field test
Prior to water maze testing, the rats were individually
housed in a rectangular container that was made of darkpolyethylene (60 × 60 × 30 cm) to provide the best
contrast to the white rats in a dimly lit room equipped with
a video camera above the center of the room, and their
locomotor activities (animal’s movements) were then mea-
sured. The locomotor activity indicated by the speed and
distance of movements was monitored by a computerized
video-tracking system using the S-MART program (PanLab
Co., Barcelona, Spain). After 5 min of adaptation, the
distance they traveled in the container was recorded for
another 5 min. The locomotor activity was measured in
centimeters. The floor surface of each chamber was
thoroughly cleaned with 70% ethanol between tests.
Immunohistochemistry
For immunohistochemical studies, three rats in each
groups were deeply anesthetized with sodium pentobar-
bital (80 mg/kg, by intraperitoneal injection) and perfused
through the ascending aorta with normal saline (0.9%),
followed by 300 ml (per rat) of 4% paraformaldehyde in
0.1 M phosphate-buffered saline (PBS). The brains were
removed in a randomized order, post-fixed over-night,
and cryoprotected with 20% sucrose in 0.1 M PBS at 4°C.
Coronal sections 30 μm thick were serially cut through
the hippocampus using a cryostat (Leica CM1850; Leica
Microsystems Ltd., Nussloch, Germany). The sections
were obtained according to the rat atlas of Paxinos and
Watson [29]. The primary antibodies against the following
specific antigen were used: choline acetyltransferase (ChAT;
sheep polyclonal ChAT, 1:2,000 dilution, Cambridge
Research Biochemicals Co., Bellingham, UK), acetyl-
cholinesterase (AchE; goat polyclonal AchE, 1:2,000
dilution, Santa Cruz Biotechnology Inc., CA, USA),
BDNF (rabbit polyclonal BDNF, 1:200 dilution, Cell
signaling., Bostron, MA, USA) and CREB (rabbit polyclonal
CREB, 1:250 dilution, Cell signaling., Bostron, MA, USA).
Briefly, the sections were incubated with primary antiserum
in PBST (PBS plus 0.3% Triton X-100) for 72 h at 4°C. The
sections were incubated for 120 min at room temperature
with secondary antibody. The secondary antibodies were
obtained from Vector Laboratories Co. (Burlingame, CA,
USA) and diluted 1:200 in PBST containing 2% normal
serum. To visualize immunoreactivity, the sections were
incubated for 90 min in avidin-biotin-peroxidase complex
(ABC) reagent (Vectastain Elite ABC kit; Vector Labs. Co.),
and incubated in a solution containing 3,3’-diaminobenzi-
dine (DAB; Sigma) and 0.01% H2O2 for 1 min. Finally, the
tissues were washed in PBS, followed by a brief rinse
in distilled water, and mounted individually onto
slides. Images were captured using the AxioVision 3.0
imaging system (Carl Zeiss, Inc., Oberkochen, Germany)
and processed using Adobe Photoshop (Adobe Systems,
Inc., San Jose, CA, USA). The sections were viewed at
400× magnification, and the numbers of ChAT-, AchE-,
BDNF-, and CREB-labeled cells was quantified in the CA1
Figure 2 Effect of GV20 acupuncture stimulation on latency to
enter the dark compartment in the acquisition trial and the
retention test in the passive avoidance test (PAT). The rats were
randomly divided into five groups of six or seven individuals as follows:
normal group (SAL group, n = 7), the SCO-induced and saline-treated
group (SCO group as a control, n = 7), the SCO-induced and Baihui
(GV20) acupoint-stimulated group (SCO + GV20 group, n = 7), the
SCO-induced and Yangji (TE4) acupoint-stimulated group (SCO+ TH4
group, n = 6), and SCO-induced and non-acupoint (on the tail)-stimulated
group (SCO+ TA group, n = 6) every day for 5 min before SCO injection.
***p< 0.001 vs. the SAL group; #p< 0.05 vs. the SCO group.
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in at least three different hippocampal sections per rat
brain according to the stereotactic rat brain atlas of
Paxinos and Watson [29]. The counted sections were
randomly chosen from equal levels of serial sections
along the rostral-caudal axis. For measuring the number
of ChAT, AchE, BDNF and CREB-positive labeled cells
were counted only if it reached a defined darkness above
background [6]. Lightly immunolabeled cells were not
counted. Distinct brown spots indicating ChAT-, AchE-,
BDNF- and CREB-immunopositive cells were observed in
the cytoplasms and in the membranes of cone-shaped
cells in the CA1 of hippocampus. The differences in
brightness and contrast among raw images were not
adjusted, in order to exclude any possibility of subjective
selection of the immuoreactive cells.
Total RNA preparation and RT-PCR analysis
The expression levels of choline transporter 1 (CHT1),
vesicular acetylcholine transporter (VAChT), muscarinic
acetylcholine receptor type 1 (mAChR-M1), BDNF and
CREB mRNAs were determined by reverse transcrip-
tion-polymerase chain reaction (RT-PCR). The brain
hippocampus was isolated from three or four rats per
each group. The total RNA was prepared from the brain
tissues using a TRIzol® reagent (Invitrogen Co., Carlsbad,
CA, USA) according to the supplier’s instruction.
Complementary DNA was first synthesized from total
RNA using a reverse transcriptase (Takara Co., Shiga,
Japan). PCR was performed using a PTC-100 programmable
thermal controller (MJ Research, Inc., Watertown, MA,
USA). All primers were designed using published mRNA
sequences of those cytokines and a primer designing
software, Primer 3, offered by the Whitehead Institute
for Biomedical Research (Cambridge, MA, USA; www.
genome.wi.mit.edu) on the website. The PCR products
were separated on 1.2% agarose gels and stained with
ethidium bromide. The density of each band was quanti-
fied using an image-analyzing system (i-MaxTM, CoreBio
System Co., Seoul, Korea). The expression levels were
compared each other by calculating the relative density
of target band, such as CHT1, VAChT, mAChR-M1,
BDNF and CREB to that of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH).
Statistical analysis
All measurements were performed by an independent
investigator blinded to the experimental conditions. The
results in the figures are expressed as the mean ± standard
error of the means (SE). Differences within or between
normally distributed data were analyzed by analysis of
variance (ANOVA) using SPSS (Version 13.0; SPSS, Inc.,
Chicago, IL, USA), followed by Tukey’s post hoc test.
Statistical significance was set at p < 0.05.Results
Effect of acupuncture stimulation of GV20 on
SCO-induced step-through latency deficit in the passive
avoidance test
To determine whether acupuncture stimulation at the
GV20 promotes the recovery of memory dysfunction,
acupuncture was performed to the rats with SCO-induced
impairment of memory, and their memory and cognitive
functions were examined by the PAT (Figure 2). It was
verified that the rats in all groups had no physiological
defect (i.e., motor function defect) or intrinsic cognitive
impairment through acquisition trials without electric
challenge. During the time for acquisition trials, indicated
by the latencies for entering the dark compartment, there
were no significant differences among all groups. After
acquisition trials, the effect of acupuncture stimulation at
the GV20 on the retention latency was examined 24 h
after applying electric shock in the dark box in the PAT.
In the retention trials, it was shown that in the rats in the
SCO +GV20 group had significantly increased latencies
to enter the dark compartment for retention as compared
to those in the SCO group (p < 0.05). This suggests that
acupuncture stimulation of GV20, but not of TE4 or the
tail, restored memory impairment-related behavior.
Effect of acupuncture stimulation of GV20 on
SCO-induced spatial memory impairment in the water
maze test
The effect of acupuncture stimulation at the GV20 on
swimming to reach the submerged platform in the
MWM test is elucidated in Figure 3. Rats in the SAL
group rapidly learned the location of the submerged
Figure 3 Effects of GV20 acupuncture stimulation on time to
escape (latency) from water during acquisition trials using a
submerged platform (A), on the percentages of time in a probe
trial without a platform (B), and swim speed (C) in the Morris water
maze (MWM) task (n = 6-7/group). *p< 0.05, **p< 0.01, ***p< 0.001 vs.
the SAL group; #p< 0.05, ##p< 0.01 vs. the SCO group.
Figure 4 Locomotor activity counts in the open-field test
(n = 6-7/group).
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of the trials. The SCO group showed marked retardation
in escape latency, probably due to memory deficits
resulting from SCO-induced impairment of learning and
memory. The analysis of escape latency revealed that
rats in the SCO +GV20 group had significantly reducedswimming latency as compared with that in the SCO
group (p < 0.01 on days 5; Figure 3A). To investigate the
effect on spatial memory, the performance in the
probe trial on day 6 was examined by analyzing the
percentages of time spent swimming to the expected
position of the platform (Figure 3B). The swimming
times were reduced in the rats that swam directly
and without confusion to the target area where the
platform had been located. The rats with SCO injection
showed severe impairment of spatial performance in the
MWM test (p < 0.05). The rats in the acupuncture
stimulation of GV20-treated group spent more time
around the platform area than those in the SCO
group (p < 0.05). The SCO group was not significantly
different from the other groups in terms of the mean
swimming speed, as calculated by dividing the total
swim distance by latency (p > 0.05; Figure 3C). Based
on these results, rats treated with acupuncture stimulation
at the GV20 were suggested to show greater improvement
in acquisition during the hidden platform trial and,
accordingly, reached the platform quicker than the
SCO-treated rats. The results also indicated that the
swimming latency of the SCO-induced rats treating
acupuncture stimulation of GV20, but not of TE4 or the
tail, restored memory impairment-related behavior.
Effect of acupuncture stimulation of GV20 on
SCO-induced motor functions in the open field test
Open field activity was used to evaluate locomotor activity
in the rats that received repeated SCO injection for 14 days
(Figure 4). These results indicated that the rats in all
groups had no effects on their locomotor activities
(motor function) in the open-field test. Because no
significant differences in locomotor activities was observed
between all groups in the open-field test, it could be
suggested that the observed impairment of memory of the
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differences in their locomotion activities. This may reflect
an active response and water avoidance stress when the
animal is confronted with a MWM test. However, our
results suggest that the rats in all groups displayed no
anxiolytic-like behavior in the open-field test after a
pretest stress exposure in the MWM test. This indicates
that acupuncture stimulation at the GV20 did not affect
the active responses or psychomotor function as measured
by the rats’ performance in the MWM test.
Effect of acupuncture stimulation of GV20 on
SCO-induced immunohistochemical changes of ChAT,
AchE, BDNF and CREB expression in the hippocampus
Following the behavioral tasks, brain tissue samples from
the subjects were analyzed using immunohistochemistry
to investigate the effect of acupuncture stimulation at
the GV20 treatment on neuronal loss associated with
SOC-induced memory impairment. The results of
the ChAT and AchE immunoreactivity analysis in theFigure 5 Effect of GV20 acupuncture stimulation on the percentage v
acetyltransferase (ChAT)-stained neurons and acetylcholinesterase (A
Morris water maze (MWM) task (n = 3-4/group). Representative photo
(B and C), respectively. (a): ChAT expression in the SAL group, (b): ChAT e
group, (d): AchE expression in the SAL group, (e): AchE expression in the SC
cut coronally at 30 μm. Scale bar represents 50 μm. *p < 0.05, **p < 0.01 vs.hippocampal cholinergic neuron areas are shown in
Figure 5A. The number of ChAT-immunoreactive
neuronal cells in the rat hippocampus in the SCO group
was significantly decreased compared with that in the SAL
group (p < 0.05; Figure 5B). The ChAT-reactive neuronal
activity in the hippocampus was significantly increased in
the hippocampal region in the SCO+GV20 group com-
pared with that in the SCO group (p < 0.05). The results
also indicated that the SCO-induced rats treating acu-
puncture stimulation of GV20 was significantly increased
ChAT expression in the hippocampal region compared
with those in the SCO+TE4 group and the SCO +TA
group. Similarly, the number of AchE-immunopositive
neuronal cells in the rat hippocampus in the SCO group
was significantly decreased compared with that in the SAL
group (p < 0.01; Figure 5C). The AchE-reactive neuronal
activity in the hippocampus associated with SCO-induced
memory impairment was not significantly restored in the
SCO +GV20 group compared with that in the SCO group
(p > 0.05). However, rats receiving acupuncture at thealues of the mean (±standard errer, SE) number of choline
chE)-stained neurons in various hippocampal areas after the
graphs and the relative percentage values are shown in (A) and
xpression in the SCO group, (c): ChAT expression in the SCO + GV20
O group, (f): AchE expression in the SCO + GV20 group. Sections were
the SAL group; #p < 0.05 vs. the SCO group.
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in the hippocampus as compared with those in the
controls (SCO group) or rats receiving acupuncture at
the nonspecific acupoint tail or TE4 point.
Additionally, results of BDNF and CREB immunoreactiv-
ity analysis in the hippocampus are shown in Figure 6A.
The number of BDNF-immunopositive neuronal cells in
the rat hippocampus in the SCO group was significantly
decreased compared with that in the SAL group (p < 0.001;
Figure 6B). The BDNF-reactive neuronal activity in the
hippocampus was significantly increased in the hippocam-
pal region in the SCO+GV20 group compared with that
in the SCO group (p < 0.01). The results also indicated that
the SCO-induced rats treating acupuncture stimulation of
GV20 was significantly increased BDNF expression in
the hippocampal region compared with those in the
SCO + TE4 group and the SCO + TA group. Also, theFigure 6 Effect of GV20 acupuncture stimulation on the percentage v
neurotrophic factor (BDNF) and cAMP-response element-binding prot
Morris water maze (MWM) task (n = 3-4/group). Representative photog
respectively. (a): BDNF expression in the SAL group, (b) BDNF expression in
CREB expression in the SAL group, (e) CREB expression in the SCO group, (
coronally at 30 μm. Scale bar represents 50 μm. **p < 0.01, ***p < 0.001 vs. thnumber of CREB-immunopositive neuronal cells in
the hippocampus in the SCO group was significantly
decreased compared with that in the SAL group (p < 0.01;
Figure 6B). The CREB-reactive neuronal activity in the
hippocampus associated with SCO-induced memory
impairment was significantly restored in the SCO +GV20
group compared with that in the SCO group (p < 0.05).
The results also indicated that the SCO-induced rats treat-
ing acupuncture stimulation of GV20 was significantly
increased CREB expression in the hippocampal region
compared with those in the SCO +TE4 group and the
SCO +TA group. This also indicated that the expression
of ChAT, BDNF and CREB-immunopositive neuronal cells
in the hippocampus of rats treating acupuncture stimula-
tion of GV20, but not of TE4 or the tail, restored memory
impairment-related cholinergic function, and activated
BDNF and CREB expression.alues of the mean (±standard errer, SE) number of brain-derived
ein (CREB)-stained neurons in various hippocampal area after the
raphs and relative percentage values are shown in (A) and (B),
the SCO group, (c) BDNF expression in the SCO + GV20 group, (d)
f) CREB expression in the SCO + GV20 group. Sections were cut
e SAL group; #p < 0.05 and ##p < 0.01 vs. the SCO group.
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SCO-induced expression of CHT1, VAChT, mAChR-M1,
BDNF and CREB mRNAs in the hippocampus
The effect of acupuncture stimulation at the GV20 on
the expression levels of CHT1, VAChT, mAChR-M1,
BDNF and CREB mRNAs in rats with SCO-induced
hippocampus lesions was investigated using RT-PCR
analysis (Figures 7 and 8). Hippocampal expression of
CHT1 mRNA in the SCO group was significantly
decreased compared with that in the SAL group (p < 0.001;
Figure 7A). The decreased expression of CHT1
mRNA in the SCO group was significantly restored in
the SCO+GV20 group (p < 0.01; Figure 7B). Hippocampal
expression of VAChT mRNA in the SCO group was also
significantly decreased compared with that in the SAL
group (p < 0.05). The decreased expression of VAChT
mRNA in the SCO group was significantly restored in the
SCO+GV20 group (p < 0.05). Hippocampal expression of
mAChR-M1 mRNA in the SCO group was significantly
decreased compared with that in the SAL group (p < 0.01).
The decreased expression of mAChR-M1 mRNA in
the SCO group was not significantly restored in the
SCO + GV20 group (p = 0.837).
Also, hippocampal expression of BDNF mRNA in the
SCO group was significantly decreased compared
with that in the SAL group (p < 0.01; Figure 8A). The
decreased expression of BDNF mRNA in the SCO
group was significantly restored in the SCO + GV20
group (p < 0.05; Figure 8B). Hippocampal expression of
CREB mRNA in the SCO group was also significantly
increased compared with that in the SAL group (p < 0.001).
The decreased expression of CREB mRNA in the SCO
group was significantly restored in the SCO+GV20 group
(p < 0.05). This also indicated that the expression of CHT1,
VAChT, BDNF and CREB mRNAs in the hippocampus in
rats treating acupuncture stimulation of GV20, but not
of TE4 or the tail, restored memory impairment-relatedFigure 7 Effects of GV20 acupuncture stimulation on the expression of
(CHT1) and muscarinic acetylcholine receptor type 1 (mAChR-M1) mRN
PCR bands on agarose gel and their relative intensities are shown in (A) and
mRNAs were normalized to that of glyceraldehyde 3-phosphate dehydrogena
vs. the SAL group; #p < 0.05, ##p < 0.01 vs. the SCO group.cholinergic function, and activated BDNF and CREB mRNAs
expression.
Discussion
Our findings demonstrated that repeated SCO-induced
memory impairment resulted in severe performance
deficits in tests of cognitive functioning as well as
corresponding signs of neurodegeneration in the brain,
including decreased cholinergic enzyme activities and
BDNF and CREB expression in the hippocampus. Our
results showed that acupuncture stimulation at GV20
significantly improved learning and memory on the PAT,
and decreased the escape latency and increased the
number of platform crossings in the MWM test in a rat
model of AD. Acupuncture stimulation also produced
increased cholinergic enzyme activity, BDNF and CREB
immunoreactivity, and increased CHT1, VAChT, BDNF
and CREB mRNA expression in the hippocampus associ-
ated with SCO-induced memory impairment in male rats.
Thus, these studies suggest that the effects of acupuncture
stimulation at GV20 might be attributable to changes in
behavioral task-related pathways that are modulated by
the cholinergic system [30]. Further, coactivation of the
cholinergic system and the BDNF-CREB pathway in the
hippocampus might influence learning and memory
processes, which may lead to development of novel
therapeutics using acupuncture stimulation at GV20 to
treat neurodegenerative diseases [31].
In traditional oriental medicine, the GV20 acupoint is
one of the most important acupoints used to select the
Governor meridians, and is located on the highest point
of the head where all of the yang meridians meet [20,26].
Thus, GV20 acupoint stimulation is effective therapeutic-
ally following stroke and in anxiety and cognitive disorders
[32]. GV20 acupoint stimulation is also frequently used to
treat psychological maladies, as it exerts general sedative
and harmonizing effects [33]. The GV20 acupoint has avesicular acetylcholine transporter (VAChT), choline transporter 1
As in rats with SCO-induced hippocampal impairment (n = 3/group).
(B), respectively. The expression levels of VAChT, CHT1 and mAChR-M1
se (GAPDH) mRNA as an internal control. *p < 0.05, **p < 0.01, ***p < 0.001
Figure 8 Effects of GV20 acupuncture stimulation on the expression of brain-derived neurotrophic factor (BDNF) and cAMP-response
element-binding protein (CREB) mRNA in rats with SCO-induced hippocampal impairment (n = 3/group). PCR bands on agarose gel and
their relative intensities are shown in (A) and (B), respectively. The expression levels of BDNF and CREB mRNA were normalized to that of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA as an internal control. **p< 0.05, ***p< 0.001 vs. the SAL group; #p< 0.05 vs. the SCO group.
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peripheral nerve; we believe that it stimulates the
CNS to release neurotransmitters or neuromodulators
into the brain [34]. As a comparable control we also
stimulated the Yangji (TE4) acupoint, which is on a
different (large intestine) meridian; and the triple-energizer
channel, which is used to treat immune depression and
pain/neuropathy of the arm [27,35]. Interestingly, 5-min
acupuncture stimulation prior to SCO administration was
sufficient to modulate SCO-induced neurochemical and
behavioral responses. In addition, only acupuncture stimu-
lation at GV20 elicited significant responses, compared
with stimulation of another acupoint on a different merid-
ian, TE4, or of a non-acupoint on the tail. These results
indicate that stimulation of the acupuncture point
spreads rapidly throughout the body and its effect is
highly point-specific, at least in terms of modulating
SCO-induced memory impairments. Furthermore, acu-
puncture stimulation at GV20 attenuates a complex
behavioral syndrome and protects the hippocampus from
deficits [36-38].
Although some studies have aimed to elucidate the
effects of acupuncture on neurodegenerative diseases,
the effect of acupuncture on SCO-induced cognitive
deficits and behavioral and neurochemical responses has
not been reported.
To identify the effects of acupuncture stimulation at
GV20 on two types of memory (cognitive memory
and spatial learning) the PAT and MWM, respectively,
were utilized. In the PAT, acupuncture stimulation at
GV20 significantly increased step-through latency in the
memory retention trial following chronic SCO administra-
tion. During MWM trial sessions, acupuncture stimulation
at GV20 resulted in a significant reduction in escape
latency, enhanced cognitive performance, and ameliorated
the memory deficits associated with AD or dementia.
These results indicate that chronic SCO administration to
rat slows escape latency in the MWM test, whichdemonstrates deficits in spatial learning ability and
reference memory [39]. The escape latency score deter-
mined by the MWM spatial probe tests is considered to
reflect long-term spatial memory ability [39]. In the present
study, acupuncture stimulation at GV20 shortened the
escape latency without affecting swimming velocity, and
extended the duration of swimming at the location where
the platform was placed previously. This indicates that
acupuncture stimulation at GV20 significantly improved
long-term memory deficits in rats following chronic
SCO-induced damage. Based on the results of the PAT
and MWM tests, it can be postulated that chronic
SCO-induced responses play an important role in
learning acquisition and synaptic plasticity [40]. An
open-field test was also performed to rule out any
confounding motor impairments that can influence
outcomes in many behavioral tests of depression. No
significant individual differences in locomotor activity
were observed between groups, suggesting that GV20
stimulation had no effect on sensorimotor performance.
Accordingly, changes in behavioral performance in the
MWM task were likely due to improved memory rather
than differences in sensorimotor function, motor output,
or limb flexibility.
The central cholinergic pathway is known for its
critical role in learning acquisition and synaptic plasticity
in the mammalian limbic system, and ACh is another
important factor [41,42]. By treating memory-related
disorders with acupuncture stimulation at the GV20,
the salvage capacity of ACh is enhanced (through
enhanced CHT expression and activity, for instance); it also
improves cholinergic neuron function in the fronto-parietal
cortex and CA1 region of the hippocampus, and con-
tinuously induces increases in ChAT and AchE enzymatic
activities, resulting eventually in recovery of the entire
cholinergic system circulation pathway [15]. ChAT and
AchE belong to the family of enzymes that are expressed
at a high level in cholinergic neurons. ChAT is responsible
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neurotransmission in the central and peripheral nervous
systems [43]. Because ACh is rapidly hydrolyzed by AchE,
the duration of ACh action in the synaptic cleft is
dependent on AchE activity [42]. According to the
cholinergic hypothesis, memory impairment in patients
with senile dementia is due to selective and irreversible def-
icits in cholinergic function or alternation in hippocampal
functioning in the brain [41,43]. The expression and
activation of AchE and ChAT regulate the dynamic
concentration of ACh in the cholinergic synapses in
AD brain [41]. Thus, we propose that the beneficial
effects of acupuncture stimulation at GV20 in ameliorating
memory impairment could be related to an increase in
central cholinergic functioning. We also demonstrated a
significant decrease in CHT1, VAChT and mAChR-M1
mRNA levels expression in rat hippocampal tissue
following SCO-induced memory impairment in male
rats, and acupuncture stimulation at GV20 induced an
increase in CHT1 and VAChT mRNA levels, which might
contribute to increased cholinergic activity. This study
strongly suggests a direct correlation between reduced
CHT1, VAChT and mAChR-M1 mRNA levels in the
hippocampus and impaired cognition, which supports
some of the results of the work presented brain [44]. The
majority of ACh is rapidly hydrolyzed by AchE to choline.
High-affinity CHT1 recycles choline from the synaptic
cleft back to presynaptic terminals for ACh resynthesis
[45]. Of the orchestrated events leading to the regulation
of ACh release and cholinergic neurotransmission, the
rate-limiting step is the recycling of choline by CHT [46].
In the presynaptic terminals, CHTs, present in endo-
somes, predominantly localize in synaptic vesicles [46].
Also, VAChT packages newly formed ACh into synaptic
vesicles to prepare its release to the synaptic cleft. VAChT
activity may affect generation of the readily releasable
ACh pool [47,48]. Specifically, in neurons that possess
small releasable pools of synaptic vesicles, including
central cholinergic neurons, the rate of filling recycling
vesicles may be directly influenced by the level of VAChT
[37,48]. Therefore, new findings concerning the use of
CHT1 and VAChT activation in the brain to develop novel
therapeutics for healing memory deficits have been
reported in several basic and clinical studies [49]. Also,
mAChRs are G protein-coupled receptors that mediate
the actions of the neurotransmitter, acetylcholine [50].
Although ubiquitously expressed in the CNS, the
highest M1 protein expression is found in the cortex,
hippocampus, and striatum, both presynaptically and
postsynaptically [50]. Some studies suggest that mAChR-M1
receptors have a number of functions, including in
learning and memory, and are implicated in a number
of human diseases, including AD and dementia [50].
Thus, M1 agonists, in addition to their expected useas a cholinergic replacement strategy, might be of unique
value in delaying the progression of memory deficits due
to repeated SCO injection in male rats [51]. Therefore,
chronic SCO-induced memory deficits result in significant
reductions in mAChR-M1 expression in the hippocampus
and poor performance on hippocampus-dependent tasks
[50]. However, our results showed significant decreases in
mAChR-M1 mRNA expression in rat hippocampal tissue
following SCO-induced memory deficits and showed that
acupuncture stimulation at GV20 did not significantly
restore mAChR-M1 mRNA levels. Despite the lack of
statistical significance, acupuncture stimulation at GV20
resulted in a trend toward recovery of the mAChR-M1
mRNA level. The reason for the observed differences in
mAChR-M1 mRNA levels following GV20 acupuncture
stimulation of cholinergic neuron action produced by
SCO-induced memory impairment in male rats also should
be investigated further.
Many studies strongly support the role of BDNF in
modulating of synaptic function and plasticity in the
CNS during learning and memory processes in addition
to its actions related to neuronal cell survival and
prevention of neurodegeneration [52]. Further, sufficient
evidence exists to indicate that CREB regulates the
expression of genes involved in neuroplasticity, cell survival,
and long-term memory formation [53,54]. Thus, BDNF
transcription, regulated by CREB, may also be a critical
player in the adaptive neuronal responses underlying
learning and memory function [12]. Thus, a previous
study suggested a close correlation between reduced
expression of BDNF and CREB in the hippocampus
with cognitive impairment [11]. SCO-induced memory
deficits were associated with significant reductions in
BDNF and CREB expression in the hippocampus and
disruption in hippocampal function during working
memory [9,14]. We thus propose that acupuncture stimu-
lation at GV20 significantly prevented SCO-induced
reductions in BDNF and CREB expression. These findings
suggest that the beneficial effects of acupuncture stimula-
tion at GV20 include decreased SCO-induced memory
and learning deficits due to increased BDNF expression
via the CREB signaling pathway and could be related
to increased neuronal functioning [14]. We also demon-
strated significantly decreased BDNF and CREB mRNA
levels in rat hippocampal tissue following SCO-induced
memory deficits, and showed that acupuncture stimulation
at GV20 restored the BDNF and CREB mRNA levels. This
study strongly suggests a close correlation between reduced
BDNF and CREB protein levels and gene expression in the
hippocampus.
According to our results, acupuncture stimulation at
GV20 in ameliorating memory impairment could be related
to an increased in central cholinergic functioning. Thus, we
concluded that the effect of acupuncture stimulation at
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and AchE activities as changes of the cholinergic system,
furthermore, there are several major signaling pathways
implicated in learning and memory [55]. Therefore, we
also demonstrated that the levels of BDNF and CREB
expression in the hippocampus involved after acupuncture
stimulation with SCO to investigate the mechanism of the
modulating action of the cholinergic system. Our results
have shown altered BDNF and CREB expression levels in
the hippocampus with dementia in rats, accompanied by
the impairment of cognition in behavioral tests, which
might be attributed to the reduction of cholinergic activity
[56]. Some studies suggested that the cholinergic system
acted on hippocampal newborn cells via CREB signaling
[15]. The cholinergic system might activate the CREB
signaling via a change of the BDNF level in the hippocam-
pus. BDNF is known to enhance the phosphorylation of
CREB and the survival of newborn cells [15]. In the present
study, SCO reduced the BDNF level in hippocampus,
consistent with the previous studies that the deficiency of
central cholinergic system reduced the level of hippocam-
pal BDNF mRNA [6]. Therefore, our results suggested
that cholinergic activation by acupuncture stimulation
regulated the mRNA of BDNF in the hippocampus.
Taken together, we suggested that acupuncture stimulation
might have the effect on the preserving of neuronal activity
of the CREB-regulated BNDF pathway in hippocampal
cholinergic neurons by restoring ACh level.
Acupuncture improves reversible malfunctions of the
body via direct activation of various brain pathways and
thus contributes to the restoration of normal systemic
balance, probably due to regulation of neurotransmitters,
including Ach [30]. Currently, acupuncture is a relevant
complementary and alternative therapy for managing
various cognitive disorders and psychosomatic diseases,
such as stress, ischemia, and dementia [55]. Several studies
demonstrated that electroacupuncture stimulation (EA)
at GV20 and Dazhui (GV14) improves motor recovery,
and stimulates BDNF/trkB expression in rats with focal
cerebral ischemia [14,57]. Acupuncture stimulation at
Shenmen (HT7), Zusanil (ST36), Fenglong (ST40) and
Taixi (KI3) improves brain function in AD patients [58],
and acupuncture stimulation at ST36 protects against
cognitive impairment caused by cerebral multi-infarct
dementia in rats [35]. Acupuncture stimulation at GV20
alleviates the spatial memory impairment induced by
cerebral multi-infarction, as evaluated by shortened
escape latency and increased swimming time in the target
quadrant in rats [59]. Therefore, these findings suggest
that acupuncture stimulation at GV20 can ameliorate
memory-related performance in many behavioral tests as
well as modulate cholinergic neurons and regulate BDNF
and CREB expression, which supports some of the results
of this study.Some studies suggest that only 5-min acupuncture
stimulation can improve memory function in animal
models and it appears to have a therapeutic effect on
several pathological disorders. For example, the long-term
electroacupuncture at acupoints Baihui (DU20) and Zusanli
(ST36) for 5 min relieves the increased mean arterial
pressure (MAP) and cerebral abnormality in both structure
and function in spontaneously hypertensive rats (SHR),
this beneficial action is most likely mediated via inhibition
of angiotensin II type I receptor (AT1R)-endothelin
receptor (ETAR)-endothelin-1 (ET-1) pathway [56]. Also,
acupuncture stimulation to the HT7 acupoint for 5 min
significantly ameliorated learning and memory deficits
through recovery of the acetylcholine system. Acupuncture
improved performance on the spatial memory test and
protected septohippocampal cholinergic neurons from
exogenous corticosterone-induced destruction [24].
Therefore, we think that only 5-min acupuncture stimula-
tion to GV20 acupoint clearly well elicited effective re-
sponses in learning and memory functions in our results.
Our results indicated that only 5-min acupuncture to GV20
was capable of attenuating impairments of memory and
cognition and protecting the hippocampus from deficits.
Our study is basically intended to test effect of
acupuncture stimulation at GV20 on prevention of
repeated SCO-induced memory impairment rather the
cure. Therefore, in order to test acupuncture stimulation at
GV20 as the therapeutic method for improve learning and
memory in rats exposed to repeated SCO-induced memory
deficits, the acupuncture stimulation at GV20 was bilat-
erally applied before the SCO injection, and thereby we did
examine to evaluate the ability of acupuncture stimulation
at GV20 on prevention as measured by their performance
in the PAT and the MWM test. Many studies suggest that
manual acupuncture treatment at Kunlun (BL60) acupoint
before formalin injection showed significant inhibited not
only flinching behavior in the late phase of the formalin test
model but also c-Fos expression in the spinal dorsal horn
[60]. Also, Yanggu (SI5) acupuncture for 1 min immediately
prior to morphine injection has been shown to suppress
the reinstatement of morphine-seeking behavior selectively
through reducing the motivation for drug via GABA
receptor system [61]. Therefore, our results showed that
acupuncture stimulation at GV20 for 5 min immediately
prior to SCO injection might be attributable to changes in
behavioral task-related pathways that are modulated by
the cholinergic system.
Conclusion
The present study demonstrated that the cognitive deficits
and memory impairment observed after SCO-induced
hippocampal lesion are closely related to the degeneration
of cholinergic neurons and the BDNF-CREB pathway;
acupuncture stimulation at GV20 significantly ameliorated
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system. Moreover, the improvement in SCO-induced
cognitive decline following acupuncture stimulation at
GV20 could also be due to the alleviation of cholinergic
neurochemical abnormalities and activation of BDNF and
CREB expression. In conclusion, acupuncture stimulation
at GV20 may be a useful alternative therapy for AD-type
dementia.
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